Cronos Group completes €57.5 million CanAdelaar acquisition

• Cronos Group acquired all outstanding CanAdelaar shares for a base purchase price of €57.5 million.
• The transaction expands the company's European operating footprint, with the stock trading up at $3.20.
• The company plans to introduce its proprietary genetics and products through the newly acquired Netherlands platform.

Cronos Group (NASDAQ:CRON) completed its acquisition of CanAdelaar for a base purchase price of €57.5 million.

Increased market competition primarily drove the acquired business's earnings decline from €24.2 million during the previous year.

The acquisition establishes a Netherlands operating platform within the Wietexperiment adult-use cannabis pilot.

The final transaction requires additional cash payments equal to half of the acquired business's normalized earnings.

The company plans to introduce its genetics.

The acquired business previously recorded annualized first-half 2026 revenue of €41.6 million and adjusted earnings of €20.1 million.

The purchasing subsidiary waived all contractual closing conditions while the seller provided limited regulatory indemnities.